VEGFA and non-small cell lung carcinoma: In the E4599 study, high VEGF levels in pretreatment plasma of 878 patients with advanced stage NSCLC, who received combinational treatment of bevacizumab plus chemotherapy, correlated with increased overall response but had no predictive outcome on survival (Dowlati et al., 2008).